Chevy Chase Trust Holdings LLC Sells 3,701 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Chevy Chase Trust Holdings LLC trimmed its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 3.9% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 92,329 shares of the medical research company's stock after selling 3,701 shares during the period. Chevy Chase Trust Holdings LLC owned 0.05% of IQVIA worth $16,278,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of IQV. Vanguard Group Inc. raised its stake in shares of IQVIA by 0.5% in the fourth quarter. Vanguard Group Inc. now owns 20,131,734 shares of the medical research company's stock worth $3,956,087,000 after buying an additional 105,504 shares during the period. Canada Pension Plan Investment Board raised its stake in IQVIA by 20.0% during the 4th quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company's stock worth $841,461,000 after acquiring an additional 712,958 shares during the period. Geode Capital Management LLC lifted its holdings in IQVIA by 1.9% during the fourth quarter. Geode Capital Management LLC now owns 4,175,524 shares of the medical research company's stock valued at $818,315,000 after purchasing an additional 77,981 shares in the last quarter. Invesco Ltd. increased its stake in shares of IQVIA by 53.4% in the fourth quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company's stock worth $509,012,000 after purchasing an additional 902,226 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. raised its position in shares of IQVIA by 2.5% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,438,726 shares of the medical research company's stock valued at $481,380,000 after purchasing an additional 59,426 shares during the period. 89.62% of the stock is owned by institutional investors.

IQVIA Trading Down 0.3%

Shares of IQV stock traded down $0.50 on Friday, reaching $157.66. 216,049 shares of the company's stock were exchanged, compared to its average volume of 1,971,035. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $252.88. The stock has a market capitalization of $27.27 billion, a PE ratio of 21.50, a P/E/G ratio of 1.74 and a beta of 1.28. The company's fifty day simple moving average is $148.98 and its 200 day simple moving average is $174.85. The company has a current ratio of 0.82, a quick ratio of 0.82 and a debt-to-equity ratio of 2.19.

IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, topping analysts' consensus estimates of $2.63 by $0.07. The business had revenue of $3.83 billion for the quarter, compared to analyst estimates of $3.77 billion. IQVIA had a net margin of 8.61% and a return on equity of 29.16%. The company's quarterly revenue was up 2.5% compared to the same quarter last year. During the same period last year, the company posted $2.54 earnings per share. As a group, analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on IQV shares. Truist Financial cut their price target on IQVIA from $263.00 to $216.00 and set a "buy" rating for the company in a research note on Thursday, April 10th. Barclays cut their target price on IQVIA from $170.00 to $165.00 and set an "equal weight" rating for the company in a research report on Wednesday, May 7th. HSBC cut IQVIA from a "buy" rating to a "hold" rating and lowered their price target for the stock from $260.00 to $160.00 in a report on Friday, April 25th. UBS Group reduced their price objective on shares of IQVIA from $255.00 to $185.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Finally, Robert W. Baird lowered their target price on shares of IQVIA from $195.00 to $161.00 and set a "neutral" rating on the stock in a report on Wednesday, May 7th. Eight research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $226.32.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.